Biogen Q3 results better than expected, updrades guidance

The US-based biotech company Biogen has released its Q3 report for 2021, stating that sales and revenue decrease was smaller than expected – subsequently, financial guidance is upgraded.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

The US premarket indicator for Biogen stock is up 1.8 percent at USD 273.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs